Replimune

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Replimune and other ETFs, options, and stocks.

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. 

CEO
Philip Astley-Sparke
CEOPhilip Astley-Sparke
Employees
206
Employees206
Headquarters
Woburn, Massachusetts
HeadquartersWoburn, Massachusetts
Founded
2015
Founded2015
Employees
206
Employees206

REPL Key Statistics

Market cap
991.06M
Market cap991.06M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
301.41K
Average volume301.41K
High today
$20.07
High today$20.07
Low today
$19.31
Low today$19.31
Open price
$19.50
Open price$19.50
Volume
107.22K
Volume107.22K
52 Week high
$31.19
52 Week high$31.19
52 Week low
$13.05
52 Week low$13.05

REPL News

Benzinga 6d
Replimune to Host Virtual Investor Event on December 7, 2022 - Replimune Group - Benzinga

WOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. REPL, a clinical stage biotechnology company pioneering the development of a novel class o...

Replimune to Host Virtual Investor Event on December 7, 2022 - Replimune Group - Benzinga

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

REPL Earnings

-$1.75
-$1.17
-$0.58
$0.00
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Q1 FY23
Q2 FY23
Q3 FY23
Estimated
per share
Estimated per share
Actual
Expected Feb 2, Pre-Market
ActualExpected Feb 2, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.